Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML
Othman, J. Potter, N. Freeman, S. D. McCarthy, N. Jovanovic, J. Runglall, M. Canham, J. Thomas, I. Johnson, S. Gilkes, A.
Othman, J.
Potter, N.
Freeman, S. D.
McCarthy, N.
Jovanovic, J.
Runglall, M.
Canham, J.
Thomas, I.
Johnson, S.
Gilkes, A.
Abstract
We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203.
Description
Date
2025
Publisher
Collections
Keywords
Type
Article
Citation
Othman J, Potter N, Freeman SD, McCarthy N, Jovanovic J, Runglall M, et al. Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML. Blood. 2025 Oct 9;146(15):1862-7. PubMed PMID: 40768751. Epub 2025/08/06. eng.